The NOAH trial [8] demonstrated that the addition of anti-HER2 treatment to neoadjuvant chemotherapy significantly improved the pCR rate and reduced the risk of recurrence and progression in patients with BC. This evidence concerns the gene ERBB2 and breast cancer.